VEGF mRNA is stabilized by Ras and tyrosine kinase oncogenes, as well as by UV radiation - Evidence for divergent stabilization pathways

被引:50
作者
White, FC
Benehacene, A
Scheele, JS
Kamps, M
机构
[1] Department of Pathology, UCSD School of Medicine, La Jolla, CA
关键词
VEGF; oncogenes; hypoxia; genistein; farnesyl transferase competitor; signal transduction;
D O I
10.3109/08977199709021520
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Vascular Endothelial Growth Factor (VEGF) is a pivotal endothelial cell mitogen that mediates both normal and pathological angiogenesis. Although expressed at very low levels in cells not undergoing vascularization, VEGF mRNA is transiently upregulated and stabilized by a variety of extracellular stimuli, and is persistently upregulated and stabilized in many human tumor cell lines (White et al., 1995). Here we demonstrate that oncogenic activation of tyrosine protein kinases and Ras proteins induce a 6- to 16-fold increase in the abundance of VEGF mRNA and a 3- to 5-fold increase in the stability of VEGF mRNA, suggesting that persistent activation of signaling pathways induced by these oncoproteins accounts for overexpression of VEGF in a significant fraction of human tumors,ln addition to these oncoproteins, ultraviolet (UV) radiation upregulated and stabilized VEGF mRNA 15- and 5-fold, respectively. While the tyrosine kinase inhibitor, genistein, blocked VEGF upregulation by activated tyrosine protein kinases, and the Ras inhibitor, N-Acetyl-S-trans-farnesyl-L-cysteine (AFC), eliminated VEGF expression in cells transformed by v-Ras, neither agent blocked upregulation by hypoxia or UV radiation. These data argue that multiple divergent pathways upregulate and stabilize VEGF mRNA.
引用
收藏
页码:199 / 212
页数:14
相关论文
共 58 条
[1]   EFFECTS OF PROTEIN-TYROSINE KINASE INHIBITORS WITH DIFFERENT MODES OF ACTION ON TOPOISOMERASE ACTIVITY AND DEATH OF IL-2-DEPENDENT CTLL-2 CELLS [J].
AZUMA, Y ;
ONISHI, Y ;
SATO, Y ;
KIZAKI, H .
JOURNAL OF BIOCHEMISTRY, 1995, 118 (02) :312-318
[2]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[3]  
Belasco J.G., 1993, CONTROL MESSENGER RN, P3
[4]   EXPRESSION OF THE VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE IN CENTRAL-NERVOUS-SYSTEM NEOPLASMS [J].
BERKMAN, RA ;
MERRILL, MJ ;
REINHOLD, WC ;
MONACCI, WT ;
SAXENA, A ;
CLARK, WC ;
ROBERTSON, JT ;
ALI, IU ;
OLDFIELD, EH .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :153-159
[5]   VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS [J].
BERSE, B ;
BROWN, LF ;
VANDEWATER, L ;
DVORAK, HF ;
SENGER, DR .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) :211-220
[6]  
BONNIEU A, 1988, ONCOGENE RES, V3, P155
[7]  
BROWN LF, 1993, AM J PATHOL, V143, P1255
[8]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].
BROWN, LF ;
BERSE, B ;
JACKMAN, RW ;
TOGNAZZI, K ;
GUIDI, AJ ;
DVORAK, HF ;
SENGER, DR ;
CONNOLLY, JL ;
SCHNITT, SJ .
HUMAN PATHOLOGY, 1995, 26 (01) :86-91
[9]  
BROWN LF, 1993, CANCER RES, V53, P4727
[10]   VASCULAR-PERMEABILITY INDUCED BY PROTEIN PRODUCT OF MALIGNANT BRAIN-TUMORS - INHIBITION BY DEXAMETHASONE [J].
BRUCE, JN ;
CRISCUOLO, GR ;
MERRILL, MJ ;
MOQUIN, RR ;
BLACKLOCK, JB ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1987, 67 (06) :880-884